Table 3.
Studies evaluating intraoperative irreversible electroporation of pancreatic cancer
|
Author
|
Patients
|
Median OS(mo)
|
Guidancemodality
|
Major adverse events
|
| Paiella et al[53], 2015 | 10 | 7.5 | US | 20% |
| Martin et al[48], 2015 | 200 | 24.9 | US | 22% |
| Kluger et al[52], 2015 | 50 | 7.7 | Not reported | 38% |
| Lambert et al[54], 2015 | 21 | 10.2 | Not reported | 24% |
| Yan et al[57], 2016 | 25 | Not reported | US | 16% |
| Vogel et al[50], 2017 | 15 | 16 | US | 53% |
| Huang et al[47], 2018 | 70 | 22.6 | US | 4% |
| Yang et al[105], 2020 | 74 | 53% (3 yr)1 | US | 12% |
| He et al[106], 2020 | 36 | 53.5% (2 yr)2 | US | 5% |
| He et al[49], 2020 | 167 | 16 | US | N/A |
1
Survival probability at 3-year.
2
Survival probability at 2-year. US: Ultrasound.